Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García C.

Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors

Neuropharmacology 2013. 75(SI): 155-163. Nº de citas: 43

[doi:10.1016/j.neuropharm.2013.07.024]

Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long JZ, Cravatt BF, Giovannoni G, Baker D.

Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors

MULTIPLE SCLEROSIS JOURNAL 2013. 19(14): 1896-1904. Nº de citas: 27

[doi:10.1177/1352458513485982]

Valhondo M, Marco I, Martín-Fontecha M, Vázquez-Villa H, Ramos JA, Berkels R, Lauterbach T, Benhamú B, López-Rodríguez ML.

New Serotonin 5-HT1A Receptor Agonists Endowed with Antinociceptive Activity in Vivo

JOURNAL OF MEDICINAL CHEMISTRY 2013. 56(20): 7851-7861. Nº de citas: 22

[doi:10.1021/jm400766k]

Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti FA, Allarà M, Sagredo O, Di Marzo V, Fernández-Ruiz J.

The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG

CELL DEATH & DISEASE 2013. 4: . Nº de citas: 64

[doi:10.1038/cddis.2013.387]

Perucho J, Casarejos MJ, Gómez A, Ruíz C, Fernández-Estevez MÁ, Muñoz MP, de Yébenes JG, Mena MÁ.

Striatal Infusion of Glial Conditioned Medium Diminishes Huntingtin Pathology in R6/1 Mice

Plos One 2013. 8(9): . Nº de citas: 9

[doi:10.1371/journal.pone.0073120]

Pazos MR, Mohammed N, Lafuente H, Santos M, Martínez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martínez-Orgado J.

Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT(1A) and CB2 receptors

Neuropharmacology 2013. 71: 282-291. Nº de citas: 132

[doi:10.1016/j.neuropharm.2013.03.027]

Gómez del Rio MA, Sánchez-Reus MI, Iglesias I, Pozo MA, García-Arencibia M, Fernández-Ruiz J, García-García L, Delgado M, Benedí J.

Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson's Disease.

CNS NEUROL DISORD-DR 2013. 12(5): 665-679.

Alvarado M, Decara J, Luque MJ, Hernandez-Folgado L, Gómez-Cañas M, Gómez-Ruiz M, Fernández-Ruiz J, Elguero J, Jagerovic N, Serrano A, Goya P, de Fonseca FR.

Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21

BIOORGANIC & MEDICINAL CHEMISTRY 2013. 21(7): 1708-1716. Nº de citas: 16

[doi:10.1016/j.bmc.2013.01.055]

Fernández-Fernández C, Decara J, Bermúdez-Silva FJ, Sánchez E, Morales P, Gómez-Cañas M, Gómez-Ruíz M, Callado LF, Goya P, Rodríguez de Fonseca F, Martín MI, Fernández-Ruíz J, Meana JJ, Jagerovic N.

Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties

ARCHIV DER PHARMAZIE 2013. 346(3): 171-179. Nº de citas: 11

[doi:10.1002/ardp.201200392]

Llorente-Folch I, Sahún I, Contreras L, Casarejos MJ, Grau JM, Saheki T, Mena MA, Satrústegui J, Dierssen M, Pardo B.

AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway

JOURNAL OF NEUROCHEMISTRY 2013. 124(3): 347-362. Nº de citas: 12

[doi:10.1111/jnc.12096]

Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J.

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 2013. 75(2): 323-333. Nº de citas: 195

[doi:10.1111/j.1365-2125.2012.04341.x]

Casarejos MJ, Perucho J, Gomez A, Muñoz MP, Fernandez-Estevez M, Sagredo O, Fernandez Ruiz J, Guzman M, de Yebenes JG, Mena MA.

Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy

JOURNAL OF ALZHEIMERS DISEASE 2013. 35(3): 525-539. Nº de citas: 64

[doi:10.3233/JAD-130050]

Granja AG, Carrillo-Salinas F, Pagani A, Gómez-Cañas M, Negri R, Navarrete C, Mecha M, Mestre L, Fiebich BL, Cantarero I, Calzado MA, Bellido ML, Fernandez-Ruiz J, Appendino G, Guaza C, Muñoz E.

A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis

JOURNAL OF NEUROIMMUNE PHARMACOLOGY 2012. 7(4): 1002-1016. Nº de citas: 82

[doi:10.1007/s11481-012-9399-3]

Pazos MR, Cinquina V, Gómez A, Layunta R, Santos M, Fernández-Ruiz J, Martínez-Orgado J.

Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function

Neuropharmacology 2012. 63(5): 776-783. Nº de citas: 96

[doi:10.1016/j.neuropharm.2012.05.034]

Ruiz C, Casarejos MJ, Rubio I, Gines S, Puigdellivol M, Alberch J, Mena MA, de Yebenes JG.

The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins

BRAIN RESEARCH 2012. 1459: 100-112. Nº de citas: 8

[doi:10.1016/j.brainres.2012.04.021]

de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández-Ruiz J.

Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects

Neuropharmacology 2012. 62(7): 2299-2308. Nº de citas: 60

[doi:10.1016/j.neuropharm.2012.01.030]

Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington's Disease: Role of CB1 and CB2 Receptors

ACS CHEMICAL NEUROSCIENCE 2012. 3(5): 400-406. Nº de citas: 58

[doi:10.1021/cn200114w]

Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J.

Cannabinoids: novel medicines for the treatment of Huntington's disease.

Recent patents on CNS drug discovery 2012. 7(1): 41-48.